Program
TRD205
A development code. Also written as “TRD205 tablets”, “TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses” and “TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses”.
In Sino Biopharmaceutical's pipeline, AT2R拮抗剂
. Its studies are mostly in Neuralgia · Hallux Valgus, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 54 open or running | phase 2since Jul 31, 2025 | Jan 19, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TRD205
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2024First study: phase 1 study in HealthyFirst studyNCT07123428 · 151 enrolled · China
- Jul 29, 2025Phase 1 study in Postoperative Analgesia After Unilateral Hallux Valgus Correction SurgeryNCT07121023 · 32 planned · China
- Jul 31, 20252 phase 2 studiesNCT07123402, NCT07121101
- Apr 8, 2026Phase 2 study in Postoperative Analgesia After Unilateral Hip ArthroplastyNCT07543796 · 200 planned · China
TargetBeta
“AT2R拮抗剂”the company's pipeline, read by Claude · source
Other programs on AGTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| LY4065967 | Eli Lilly | phase 2 | 7 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07543796Postoperative Analgesia After Unilateral Hip Arthroplasty · China | 2 | Recruiting | Jun 27, 2026 | 200 |
| NCT07123402Chronic Postoperative Neuralgia · China | 2 | By invitation | Apr 20, 2026 | 184 |
| NCT07121101Postoperative Analgesia After Unilateral Hip Arthroplasty · China | 2 | Not yet recruiting | Nov 20, 2025 | 40 |
| NCT07121023Postoperative Analgesia After Unilateral Hallux Valgus Correction Surgery · China | 1 | Not yet recruiting | Dec 27, 2025 | 32 |
| NCT07123428Healthy · China | 1 | Completed | Nov 27, 2024 | 151 |
How it is read
Names in the registry
- “TRD205 tablets”, 9 entries
- “TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses”, 1 entry
- “TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses”, 1 entry
- “TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 doses”, 1 entry
- “TRD205”, 1 entry
Codes read as this program: TRD205.
Conditions, from the studies’ own filings
- Neuralgia, 1 study
- Hallux Valgus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.